



American Heart Association®

Hypertension

# Conference Highlights – Awards and Lectures\*

## Thursday, September 8, 2022

- 3:30 pm: Arthur C. Corcoran Memorial Lecture
- 5:30 pm: The Stephanie Watts Career Development Award  
The Harry Goldblatt Award for New Investigators

## Friday, September 9, 2022

- 7:30 am: Donald Seldin Award and Lecture
- 10:00 am: Harriet Dustan Awards and Lectures
- 3:30 pm: HTN Mid-Career Award for Research Excellence  
KCVD Mid-Career Achievement Award
- 5:45 pm: Excellence Award in Hypertension Research Lectures
- 7:00 pm: Hypertension Awards Banquet Events  
*This is a ticketed event.*
  - Irvine Page-Alva Bradley Lifetime Achievement Award
  - The Marvin Moser Clinical Hypertension Award

## Saturday, September 10, 2022

- 7:30 am: Lewis K. Dahl Memorial Lecture

\* Visit [Council Named Lecturers](#) to view a list of current and previous lecturers.

## ■ EXCELLENCE AWARD FOR HYPERTENSION RESEARCH



**Joey P. Granger, PhD, FAHA**

Dr. Granger is the Guyton Distinguished Professor of Physiology and Medicine, Director of the Cardiovascular Research Center, Vice Chancellor for Research, and Dean of Graduate Studies at the University of Mississippi Medical Center. Dr. Granger is the author of over 300 manuscripts and his publications have been cited more than 24,100 times. Dr. Granger's seminal work showed that placental ischemia is an important initiating event in the pathophysiology of

preeclampsia not only causing hypertension but also the first to show endothelial, renal, and cerebral dysfunction, and most recently pre- and postpartum cardiac dysfunction. His lab discovered that in response to placental ischemia, the placenta activates soluble substances that are responsible for the symptomatic phase of the disease and serve as targets for therapeutic intervention. Dr. Granger's stature is exemplified by continuous funding from the NIH for over 40 years and numerous awards he has received from national and international organizations.

Dr. Granger has also impacted the hypertension field through his service to the greater scientific community including serving as Chair, American Heart Association Council on Hypertension (COH), and President of the American Physiological Society. It was during his tenure as chair of COH that he oversaw the merger of American Society of Hypertension (ASH) with COH. He also served as Associate Editor of the *Hypertension* journal for 20 years and was instrumental in establishing the journal as the scientific home for preeclampsia researchers

## ■ EXCELLENCE AWARD FOR HYPERTENSION RESEARCH



**Edwin K. Jackson, PhD, FAHA**

Dr. Jackson obtained a BS in pharmacy (1976) from the University of Texas at Austin and a PhD in pharmacology (1979) at the University of Texas Health Science Center at Dallas. After completing a fellowship in clinical pharmacology at Vanderbilt University, Dr. Jackson joined the Vanderbilt faculty in the Division of Clinical Pharmacology and Department of Pharmacology (1981), where he was promoted to tenured associate (1985) and full (1989) professor. In 1991, Dr. Jackson accepted a

position at the University of Pittsburgh School of Medicine where he is currently distinguished professor in the Department of Pharmacology and Chemical Biology.

His scholarly contributions include 454 peer reviewed publications, 42 book chapters and 371 published meeting abstracts. He has contributed to Goodman and Gilman's the Pharmacological Basis of Therapeutics, known as the "bible of pharmacology," for more than 30 years. Dr. Jackson's research focusses on mechanisms of genetic hypertension and roles of estradiol metabolites and purines in the cardiovascular and renal systems. Dr. Jackson and colleagues developed the concepts that: 1) enhanced coincident signaling between the Gi and Gq pathways contributes to genetic hypertension; 2) estradiol promotes cardiorenal protection via its conversion to 2-methoxyestradiol; 3) there exists an extracellular 3',5'-cAMP-adenosine pathway that is active in many organ systems; and 4) 2',3'-cAMP, a positional isomer of 3',5'-cAMP, exists in vivo and plays a role in renal diseases. Dr. Jackson and colleagues were the first to show that adenosine given during myocardial reperfusion reduces infarct size.

While further investigating the potential of adenosine as "medicine for the heart," Dr. Jackson and colleagues discovered that adenosine prevents the pathological proliferation of cardiac fibroblasts and coronary artery smooth muscle cells and elucidated the involved mechanisms. These findings motivated Dr. Jackson and colleagues to develop a novel cardiac guidewire that provides for autonomous release of adenosine directly into the "at-risk" coronary artery without thought or planning by the interventional cardiologist. While investigating the pharmacological effects of other purines, Dr. Jackson discovered that some 8-aminopurines are novel diuretics that exert antihypertensive effects and protect against strokes, pulmonary hypertension, and sickle cell disease and have anti- and reverse-aging effects.

Although Dr. Jackson's main focus is on cardiovascular/renal diseases, his investigations have contributed to breakthroughs in our understanding of the roles of adenosine in brain injury, regulation of the immune system and cancer.

## ■ IRVINE PAGE - ALVA BRADLEY LIFETIME ACHIEVEMENT AWARD



### **Alicia A. McDonough, PhD, FAHA**

Professor of Physiology and Neuroscience,  
USC Keck School of Medicine

After earning degrees in Physiology at UC Berkeley (AB) and University of Hawaii (PhD), Dr. McDonough trained in Molecular Physiology at UC San Francisco CVRI, and Columbia University then joined University of Southern California Department of Physiology in 1981.

As an American Heart Association Established Investigator, her lab defined biosynthesis and

assembly of sodium pump subunits and (patho)physiologic mechanisms controlling sodium pump isoforms across brain, heart, muscle, and kidneys. They defined sodium pump isoform distributions in human hearts and how they changed in heart failure, and how skeletal muscle sodium pump isoforms (working with kidney and gut) effect extra-renal control of potassium homeostasis. She champions these findings to support the cardiovascular benefits of raising dietary K/Na ratio.

Driven by a long-standing interest in the role of blood pressure in regulating sodium, potassium and circulating volume homeostasis, the lab group discovered that acute changes in blood pressure, AngII or PTH provoke rapid trafficking of renal sodium transporters between membrane domains. With collaborators, they defined where and how chronic changes in salts, AngII, kidney injury, and immune cytokines increase renal sodium transport along the nephron and how the resultant hypertension provokes counteracting responses to suppress sodium reabsorption, i.e., pressure natriuresis, a determinant of the blood pressure set point.

More recently, the lab characterized functional sexual dimorphisms along the female vs. male nephron over life cycle, thus, shedding light on the “female advantage” in cardiovascular disease protection. These projects have attracted attention to the key role of the kidney in balancing the intertwined homeostasis of sodium, potassium, and blood pressure. Along with a strong service record to NIH, AHA, and editorial boards, Dr. McDonough has demonstrated commitment to teaching, training, and mentoring the next generation of cardiorenal scientists.

Dr. McDonough is recipient of multiple awards including the 2009 Starling Distinguished Lectureship from the American Physiological Society (APS), the 2014 Donald Seldin Lecture from the Council on the Kidney in Cardiovascular Disease (KCVD), the Robert Schrier Lecture at ASN Kidney week (2017), the Steven Hebert Lecture (APS, 2018) and the Robert Pitts Lecture from the International Union of Physiological Sciences (2022).

## ■ ARTHUR C. CORCORAN MEMORIAL LECTURE



**Mark C. Chappell, PhD, FAHA**

Dr. Chappell's training began under a STRIDE scholarship from the NIH in the laboratory of Dr. David Jacobowitz with a Chemistry/Biochemistry degree from American University, a Ph.D. in Regulatory Biology from Cleveland State/Cleveland Clinic and post-doctoral work at Wake Forest University School of Medicine (WFUSM). His research has identified functional processing pathways of the Renin-Angiotensin System (RAS), specifically the non-classical and intracellular

components of the RAS in the brain, heart, circulation, pancreas, and kidney as related to cardiometabolic disease in hypertension, aging, sex differences, salt-sensitivity, and fetal-programmed adult cardiovascular disease in experimental models and in human subjects. His current efforts have focused on SARS-Cov-2 and the RAS in COVID-19 patients.

He has 200+ publications, H index of 76 and funding from the NIH and AHA including two different Program Project grants. He received the New Investigator Award from the Consortium for Southeastern Hypertension Control (COSEHC), is a long-time member of the American Physiological Society (APS), a Fellow of the American Heart Association, and served on editorial boards of *Hypertension*, *Journal of Hypertension*, *American Journal of Hypertension*, and the *American Journal of Physiology and Peptides*. He is a member of the NIH Reviewers Reserve following regular membership on several review committees including Hypertension and Ruth L. Kirschstein training awards.

Dr. Chappell is committed to research training nationally and through prior international exchange programs as director of Science Without Borders, and to increasing diversity training through NIH-funded Excellence in Cardiovascular Sciences Summer (EICS), Post-baccalaureate Research Education (PBRE) and Postdoctoral Research, Instruction and Mentoring Experience (PRIME) programs.

## ■ LEWIS K. DAHL MEMORIAL LECTURE



**Kailash N. Pandey, PhD, FAHA**

Dr. Pandey is a Professor and Vice Chair of Medical Research in Physiology, Tulane University School of Medicine. He received bachelor's and master's degrees from Kanpur University, India, and PhD in 1979 from University of Kentucky. He completed postdoctoral training in Biochemistry at Vanderbilt University and in 1987 was promoted to Research Assistant Professor. In 1990, he moved to the Medical

College of Georgia as an Associate Professor of Biochemistry-Molecular Biology. In 1997, he joined the Department of Physiology, Tulane School of Medicine. He has consistent funding from NIH over 30 years and published over 135 research articles, reviews, and book chapters, 260 abstracts, one Guest-Editorship of *Peptides*, and edited one book. He has served on the editorial boards of many scientific journals, including *Hypertension*, *AJP-Renal*, *Physiological Genomics*, *Endocrinology*, and *JASH*. He has extensive service to scientific organizations; including NIH study sections, and American Heart Association grant review panels. He has trained 44 postdoctoral/graduate students and has received numerous awards/honors: AHA Established-Investigator Award, Andrew-Mellon Young Faculty Award-Vanderbilt University, Outstanding Young Faculty Award-Medical College of Georgia, ASH Marion-Merrell-Dow Young Scholar Award, and Hans-Peter Krayenbuehl Award-International Academy of Cardiology.

Dr. Pandey's research has focused on natriuretic peptides (NPs)/ receptors and renin-angiotensin-system, emphasizing molecular basis of hypertension and cardiovascular diseases. He deduced amino acid sequence of NP receptor-A (NPRA) and genomic sequence of Npr1 (encoding NPRA). In collaboration with late Professor Oliver Smithies, he established global Npr1 gene-targeted mouse models of varying Npr1 gene-copies. Currently, he has developed conditional renal, vascular, and cardiac cell-specific Npr1-deleted mouse lines to study the non-systemic mechanisms of hypertension and cardiovascular disorders.

## ■ HARRIET DUSTAN AWARD AND LECTURE



### **Aletta E. Schutte, PhD**

Dr. Schutte (also known as Alta) is a SHARP Professor of Cardiovascular Medicine at the University of New South Wales with a Professorial appointment at The George Institute for Global Health in Sydney, Australia. She is also Honorary Professor at the University of the Witwatersrand and the North-West University in South Africa. Alta has contributed to over >400 publications in the field of hypertension (Google H-index 67, >79,000 citations) and ranks in the top 0.019% of 250, 197 authors in the field 'blood pressure (BP)' (Expertscape). She has supervised 61 Masters and PhD students to completion.

Professor Schutte's research interest is the early detection, prevention, and effective management of hypertension, where she has led many population and clinical studies. Originally based in South Africa, she was the Founding Director of the Hypertension in Africa Research Team (HART) and established the Medical Research Council Unit for Hypertension and was President of the Southern African Hypertension Society. Since relocating to Australia in 2020 she leads projects and trials to improve blood pressure control.

Alta is an invited author of the Lancet Commission on Hypertension and of the WHO's Technical Specifications Report for Automated Non-Invasive Blood Pressure Measuring Devices. She is the Co-Chair of STRIDE BP, an international scientific non-profit organization listing blood pressure devices validated for accuracy. She is a Steering Committee Member of the May Measurement Month global blood pressure awareness campaign with over 5 million people screened.

She is the Immediate Past President of the International Society of Hypertension (2018–2020) during which time she initiated the development of the 2020 ISH Global Hypertension Practice Guidelines. Alta is an Associated Editor of *Hypertension*, *Hypertension Research* and the *European Journal of Preventive Cardiology*, and editorial board member of several other hypertension journals.

## ■ HARRIET DUSTAN AWARD AND LECTURE



### **Maria Luisa Soledad Sequeira Lopez, MD, FAHA**

Dr. Sequeira Lopez received her MD from the University of Buenos Aires, Argentina (1990), followed by a Pediatric Residency and Fellowship at the Hospital Garrahan. She joined the University of Virginia in 1998, where she received postdoctoral training in kidney development and renin cell differentiation. In 2000, she obtained a HHMI Postdoctoral Fellowship followed by continuous NIH funding.

She was elected a Fellow of the American Heart Association in 2013, received the Pinn Scholars Award and the Harrison Distinguished Professorship from UVA, among others.

Dr. Sequeira Lopez made fundamental contributions to our understanding of kidney vascular development, disease, and regeneration. She identified the earliest progenitors for all the cells in the kidney vasculature and the mechanism whereby they differentiate into renin, smooth-muscle, and endothelial cells. She demonstrated the crucial role of kidney vascular progenitors in tissue regeneration with implications in kidney disease and hypertension. Recently, she elucidated the structure and mechanism of the enigmatic renin cell baroreceptor.

She is an extraordinary mentor for students and junior faculty: her trainees received international awards and are successful academicians. She is a leader in advocating faculty well-being and the inclusion of women and minorities at all levels of the academic/administrative spectrum. Dr. Sequeira Lopez is a reviewer for NIH, AHA, and European Agencies. She has been a member of several AHA Council of Hypertension and APS committees and is currently an Associate Editor for *Clinical Science*, *AJP-Renal*, and a Guest Editor for *Hypertension*. She is an internationally recognized scientist and was the chair of the 2020 Angiotensin Gordon Research Conference.

## ■ DONALD SELDIN LECTURE



**Orson W. Moe, MD**

Dr. Moe received his medical degree from the University of Toronto and is currently Professor of Mineral Metabolism, Internal Medicine, and Physiology at the University of Texas Southwestern Medical Center, where he is a physician, scientist, and teacher. His administrative duties include Director of the Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, and former Chief of the Nephrology Division.

He is the holder of the Charles and Jane Pak Distinguished Chair in Mineral Metabolism Research and the Donald Seldin Professorship in Clinical Investigation. He has received prestigious research awards including the Jack Coburn Award and Endowed Lectureship in Mineral Metabolism (2013) and the Donald W. Seldin Endowed Lectureship in Renal Physiology (2018) from the American Society of Nephrology.

## ■ COUNCIL ON THE KIDNEY IN CARDIOVASCULAR DISEASE MID-CAREER ACHIEVEMENT AWARD



**James McCormick, PhD, FAHA**

Dr. McCormick earned his BSc. (First Class Honours) and PhD from the University of Edinburgh. He then joined the laboratory of Dr. David Pearce at UCSF, where he was funded by an American Heart Association Postdoctoral Award. He later joined the laboratory of Dr. David Ellison at Oregon Health and Science University, receiving a K01 award from the NIDDK and a Beginning Grant-In-Aid from the

American Heart Association.

Since then, he has made significant contributions to understanding of the role of the NaCl cotransporter (NCC) in hypertension and K<sup>+</sup> handling. Key contributions include identifying kidney-specific isoforms of the NCC-activating protein kinase SPAK, determining the role of the K<sup>+</sup> channel Kir4.1 in NCC regulation, and determining the mechanism by which mutations in the ubiquitin ligase Cullin 3 cause hypertension. This work has led to the concept of the “potassium switch” via which NCC activity is turned on or off to maintain K<sup>+</sup> homeostasis under normal physiological conditions.

As a result of his expertise, Dr. McCormick has established many successful collaborations, both nationally and internationally, and his work has been published in high impact journals including *Cell Metabolism* and *JCI*. He was promoted to Associate Professor in 2018 and is currently funded by two R01s from the NIDDK (one as a PI, one as a co-I). Dr. McCormick has received Institutional teaching awards. He has served on the School of Medicine Research Committee, the Promotion and Tenure Committee, the American Physiological Finance Committee, and many review panels for the NIH and American Heart Association.

## ■ COUNCIL ON HYPERTENSION MID-CAREER AWARD FOR RESEARCH EXCELLENCE



**Justin L. Grobe, PhD, FAHA**

Dr. Dr. Grobe is an Associate Professor of Physiology and Biomedical Engineering at the Medical College of Wisconsin (MCW). He trained at Hope College in Biology and Chemistry before completing his PhD in Pharmacodynamics at the University of Florida. He completed postdoctoral training and was recruited onto the faculty of Pharmacology at the University of Iowa in 2012.

In 2019 he moved to MCW, and serves as the founding director of a Comprehensive Rodent Metabolic Phenotyping Core facility. Justin's research program encompasses multiple areas including hypothalamic control of cardiometabolic function, neurohormonal dysfunctions of pregnancy that contribute to preeclampsia and the cardiometabolic programming that is associated with premature birth, technology development to enable advanced cardiometabolic phenotyping in small animals, and the role of the gut microbiome in cardiovascular and metabolic health.

He has mentored 25 medical and undergraduate, 8 predoctoral, and 6 postdoctoral trainees who have earned numerous prestigious fellowships and awards. He has served in a wide array of leadership positions within the American Heart Association, including many positions within the Council on Hypertension. He has served on the editorial board of *Hypertension* for a decade, and as a section editor for *Physiological Genomics*. To date, he has published over 110 manuscripts, received an array of notable career and research recognition awards, holds several domestic and international patents, and is supported by multiple ongoing grants from the NIH and the AHA.

## ■ HARRY GOLDBLATT AWARD FOR EARLY CAREER INVESTIGATORS



### **Camilla Ferreira Wenceslau, PhD, MS, FAHA**

Dr. Wenceslau received her Master (2007) and PhD (2012) degrees in Human Physiology from the University of Sao Paulo, Brazil. During this time, she had the opportunity to train abroad at the Autonomous University of Madrid, Spain. She then went to Augusta University, Medical College of Georgia and joined the laboratory of Dr. Clinton Webb. Camilla received a

postdoctoral fellowship from the American Heart Association, and she was subsequently awarded a K99/R00 grant from the NIH. In two years as an Assistant Professor at the University of Toledo College of Medicine & Life Science, Toledo, OH, Camilla received her first R01 award from NHLBI, then she was recruited as an Associate Professor to a new endeavor at The University of South Carolina School of Medicine Columbia, helping launch the Cardiovascular Translational Research Center (CTRC).

Dr. Wenceslau is interested in better understanding the mechanisms associated with vascular remodeling and injury prior to the onset of hypertension. Her lab has also developed an interest in the role of immunoreceptors, vasculature mechanics and blood pressure control.

Camilla is a standing member of Integrative Vascular Physiology and Pathology (IVPP) NIH study section, and she has published ~60 manuscripts. In 2020, Camilla was the recipient of the John Laragh Research Award from the American Journal of Hypertension. Camilla is also an outstanding mentor. Her trainees have received more than 19 awards including New Investigator Awards from the AHA's Council on Hypertension, APS Cardiovascular Section Research Recognition Awards, two Fulbright Fellowship and others.

## ■ THE MARVIN MOSER CLINICAL HYPERTENSION AWARD



**Vesna Garovic, MD, PhD, FAHA**

Dr. Garovic is Professor of Medicine and Obstetrics & Gynecology, and Chair, Division of Nephrology and Hypertension, Mayo Clinic Rochester, MN. She is Director of the Clinical Research and Trials Unit (CRTU), Mayo Clinic Center for Clinical and Translational Science. Her research on hypertension in pregnancy has been NIH-funded for 15 years; she has over 170 peer-reviewed papers.

Dr. Garovic has been instrumental in developing a hypertension in pregnancy consultative service for Mayo that provides inpatient and outpatient care to pregnant patients from Minnesota and surrounding states (Iowa and Wisconsin), in areas where this expertise is missing. She was instrumental in the success of the FAITH! (Fostering African American Improvement in Total Health) Program, the first academic–community partnership between Mayo Clinic and African American churches in Minnesota with the focus on uncontrolled hypertension, and in developing a superspecialist, virtual consult program in obstetrical hypertension in collaboration with the University of Mississippi Medical Center, Jackson.

Dr. Garovic also established the Mayo Native American Workgroup, for clinical and research efforts aimed at improving cardiovascular health and blood pressure in native Indian community. She is Editor-in-Chief for *Hypertension in Pregnancy*, Associate Editor and Section editor for *Women's Health and Medicine of Sex Differences*, *Mayo Clinic Proceedings*, and editor for preeclampsia *Current Hypertension Reports*.

## ■ STEPHANIE WATTS CAREER DEVELOPMENT AWARD

Supported by the Council on Hypertension's Trainee Advocacy Committee (TAC) and Data Sciences International (DSI)

This award honors the advocacy work of Dr. Stephanie Watts. Dr. Watts is an exemplary mentor, who is avid to assist her trainees and many others to reach their career goals and become accomplished scientists.

Finalists will present their project pitch during a special session where one winner will be selected. The winner will receive a complete Data Sciences International (DSI) 4-animal telemetry system.



**John Henry Dasinger, PhD**

Dr. Dasinger is a senior postdoctoral fellow in the Department of Physiology at the Medical College of Georgia of Augusta University. He received his PhD in Physiology and Biophysics from the University of Mississippi Medical Center under Dr. Barbara Alexander before joining Dr. David Mattson as a postdoctoral fellow. Under Dr. Mattson's guidance, Dr. Dasinger's research is focused on the role of inflammation in hypertension with a specific interest in preeclampsia and maternal health.

Dr. Dasinger has received several awards at both the pre and postdoctoral levels from the American Heart Association and the American Physiological Society for his research, with the most recent being the 2021 Council on Hypertension Early Career Oral Presentation Award. He was recently awarded a K99 Pathway to Independence Award from the NIH to investigate the contribution of reactive oxygen species from T cells during preeclampsia and the long-term renal complications associated with an adverse pregnancy.



**Allison E. Norlander, PhD**

Dr. Norlander attended and received her undergraduate degree from the University of Pittsburgh in Microbiology with Summa Cum Laude distinction in 2012. She then matriculated into the Interdisciplinary Graduate Program at Vanderbilt University in 2012 and joined the laboratories of Drs. David Harrison and Meena Madhur to pursue her PhD. Her research focused on elucidating the effects of salt on the generation of IL-17A producing T helper 17 (Th17) cells during hypertension, as well as the impact IL-17A had on the kidney during hypertension. Dr. Norlander received an F31 to support her during her graduate studies.

Dr. Norlander joined the laboratory of Dr. Stokes Peebles at Vanderbilt University Medical Center in 2017 for her postdoctoral fellowship during which she sought to determine the effect of prostaglandin I<sub>2</sub> (PGI<sub>2</sub>) on T regulatory cells (Treg) during allergic inflammation. She received an F32 to support her during her postdoctoral studies and is now a Research Instructor at Vanderbilt University Medical Center after having received a K99/R00 Pathway to Independence Award to investigate how PGI<sub>2</sub> augments immune cell function in hypertension. The focus of Dr. Norlander's current and future research will be studying how naturally occurring substances, like salt and PGI<sub>2</sub>, affect T cells and dendritic cells and regulate or promote inflammation in hypertension.



**Noha M. Shawky, PhD, MSc**

Dr. Shawky is an assistant professor in the Department of Cell and Molecular Biology at the University of Mississippi Medical Center. Her research is focused on the cardiovascular health of hyperandrogenemic females (as seen in women with polycystic ovary syndrome (PCOS)) and their offspring. PCOS is the most common endocrine disorder affecting 6% to 12% of US women.

Although our understanding of the role of androgens in females under physiological and pathological conditions has increased significantly, large gaps in our knowledge still exist. Using a PCOS rat model that mimics most of the characteristics of the syndrome, Dr. Shawky is studying the blood pressure changes with/without western diet consumption in hyperandrogenemic females, the involved mechanisms, and the sex differences in the consequences seen in the blood pressure of their offspring as adults.

Dr. Shawky has been awarded prestigious awards during her career including a Basic Science Forum for Emerging Kidney Scientists Young Investigator Award (American Society of Nephrology, 2020), Council on the Kidney in Cardiovascular Diseases New Investigator Travel Award (American Heart Association, 2020), Caroline tum Suden/Francis A. Hellebrandt Professional Opportunity Award (American Physiological Society, 2020) and top 10% of abstracts submitted to the Council on Hypertension (2019). In addition, she was previously awarded a pre-doctoral joint supervision scholarship (2013), and a post-doctoral fellowship (American Heart Association, 2020).

Dr. Shawky is currently a Research Project Leader on the Phase 2 submission of the Mississippi Center of Excellence in Perinatal Research COBRE grant. In this project, she will be studying the impact of maternal hyperandrogenemia on the cardiovascular health of both male and female offspring.

### ***Are You a Member?***

Join today and take advantage of career-enhancing benefits as an AHA Professional Member, including:

- Networking with key science leaders
- Up to \$500,000 awarded annually in Council awards & grants
- Opportunities to present your science at AHA scientific meetings

Join today at [professional.heart.org/membership](https://professional.heart.org/membership).